What does systems biology mean for drug development?

Area of Science:

• Cellular and Molecular Biology
• Systems Biology
• Pharmacology

Background:

• Cellular complexity and flexibility are increasingly understood through advanced molecular analytics like proteomics, genomics, and metabolomics.
• Cellular networks contain more molecular species than predicted by genomics, with rapid post-translational modifications and chemical side reactions altering protein targets.
• Many key biological reactions involve low-affinity, low-selectivity interactions, enabling cellular flexibility and redundancy.

Purpose of the Study:

• To highlight the limitations of traditional single-target drug discovery for complex diseases.
• To advocate for a paradigm shift towards multi-target drug discovery.
• To emphasize the need for novel computational and mathematical approaches to model complex biological systems.

Main Methods:

• Analysis of systems biology principles and molecular analytics data.
• Review of current drug discovery paradigms and their limitations.
• Exploration of multi-target drug approaches and their potential.

Main Results:

• Traditional "one-target, one-disease" drug discovery is increasingly unsuccessful for complex disorders like cancer and neurodegenerative diseases.
• Multi-target drug approaches offer a promising strategy to increase the drugable proteome and develop novel therapeutics with potentially fewer adverse effects.
• Successful multi-target strategies have been applied to diseases including atherosclerosis, cancer, depression, psychosis, and neurodegenerative disorders.

Conclusions:

• A paradigm shift towards systemic, multi-target drug discovery is necessary to address complex diseases effectively.
• Developing novel computational and mathematical models is crucial for analyzing complex biological data and identifying potential systemic drugs.
• Targeting cellular function as a system, rather than individual proteins, expands therapeutic possibilities and may reduce drug toxicity.